Search research articles
Contact Us
Filters
Showing results (101-110 of 223) with videos related to
Page
of 23
Sort By:
The Prostate
|
January 15, 2005
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells
David Z Qian, Mingqiang Ren, Yongfeng Wei, et al.
Oncotarget
|
September 18, 2015
Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model
Dudley W Lamming, Nicole E Cummings, Antonella L Rastelli, et al.
Plos One
|
November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression
Leigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Molecular Cancer Therapeutics
|
January 24, 2007
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
Yukihiko Kato, Brenda C Salumbides, Xiao-Fei Wang, et al.
Oncotarget
|
December 20, 2013
Dietary protein restriction inhibits tumor growth in human xenograft models
Luigi Fontana, Remi M Adelaiye, Antonella L Rastelli, et al.
Cancer
|
August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Plos One
|
May 15, 2013
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model
Subroto Chatterjee, Nezar Alsaeedi, Jennifer Hou, et al.
Oncotarget
|
April 17, 2017
Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men
James R Marshall, Raymond F Burk, Rochelle Payne Ondracek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma
Xiao-Fei Wang, David Z Qian, Mingqiang Ren, et al.
The Prostate
|
September 7, 2006
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
John T Isaacs, Roberto Pili, David Z Qian, et al.
Page
of 23
Search research articles
Search
Showing results (101-110 of 223) with videos related to
Sort By:
Page
of 23
The Prostate
|
January 15, 2005
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells
David Z Qian, Mingqiang Ren, Yongfeng Wei, et al.
Oncotarget
|
September 18, 2015
Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model
Dudley W Lamming, Nicole E Cummings, Antonella L Rastelli, et al.
Plos One
|
November 17, 2011
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression
Leigh Ellis, Kristin Lehet, Swathi Ramakrishnan, et al.
Molecular Cancer Therapeutics
|
January 24, 2007
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma
Yukihiko Kato, Brenda C Salumbides, Xiao-Fei Wang, et al.
Oncotarget
|
December 20, 2013
Dietary protein restriction inhibits tumor growth in human xenograft models
Luigi Fontana, Remi M Adelaiye, Antonella L Rastelli, et al.
Cancer
|
August 28, 2009
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley, Dana Rathkopf, Rodney Dunn, et al.
Plos One
|
May 15, 2013
Use of a glycolipid inhibitor to ameliorate renal cancer in a mouse model
Subroto Chatterjee, Nezar Alsaeedi, Jennifer Hou, et al.
Oncotarget
|
April 17, 2017
Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men
James R Marshall, Raymond F Burk, Rochelle Payne Ondracek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma
Xiao-Fei Wang, David Z Qian, Mingqiang Ren, et al.
The Prostate
|
September 7, 2006
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer
John T Isaacs, Roberto Pili, David Z Qian, et al.
Page
of 23